{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:51Z","timestamp":1787628111546,"version":"build-2736575974"},"reference-count":57,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kite"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2554516","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:56:16Z","timestamp":1758009376000},"page":"1550-1562","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Navigating the economic value of treatment sequencing in large B-cell lymphoma: insights into optimizing value and patient outcomes of CAR T-cell and other available therapies in Brazil"],"prefix":"10.1080","volume":"28","author":[{"given":"Samir","family":"Nabhan","sequence":"first","affiliation":[{"name":"Bone Marrow Transplantation, Oncology and Hematology Unit, Universidade Federal do Paran\u00e1","place":["Curitiba, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Kievit","sequence":"additional","affiliation":[{"name":"Maple Health Group","place":["New York City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Blissett","sequence":"additional","affiliation":[{"name":"Maple Health Group","place":["New York City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Ball","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"e_1_3_6_2_1","volume-title":"Diffuse large B cell lymphoma","author":"Padala SA","year":"2023","unstructured":"Padala SA, Kallam A. Diffuse large B cell lymphoma. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01501"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.11.011"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19860"},{"key":"e_1_3_6_8_1","unstructured":"Gov.BR. Anvisa approves advanced therapy product for cancer treatment. 2022 [17 July 2024]. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2022\/anvisa-aprova-produto-de-terapia-avancada-para-tratamento-de-cancer"},{"key":"e_1_3_6_9_1","unstructured":"Gov.BR. Anvisa approves 3rd advanced therapy product for cancer treatment. 2022 [17 June 2024]. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2022\/anvisa-aprova-3o-produto-de-terapia-avancada-para-tratamento-do-cancer"},{"key":"e_1_3_6_10_1","unstructured":"RESOLUTION-RE No. 124 OF JANUARY 11; 2024 N\u00b0 10 segunda-feira 15 de janeiro de 2024."},{"key":"e_1_3_6_11_1","unstructured":"GOV.BR. Consultations. EPKINLY; 2023 [17 July 2024]. Available from: https:\/\/consultas.anvisa.gov.br\/#\/bulario\/q\/?nomeProduto=EPKINLY"},{"key":"e_1_3_6_12_1","unstructured":"EPKINLY\u2122 (epcoritamab-bysp). Prescribing Information (revised 5\/2023); 2023 [17 June 2024]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761324s000lbl.pdf"},{"key":"e_1_3_6_13_1","unstructured":"Gov.BR. Drug Price Lists; 2024 [17 July 2024]. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/cmed\/precos"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.512"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.510"},{"key":"e_1_3_6_16_1","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. NICE process and methods [PMG36]. 2022 [17 July 2024]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2"},{"key":"e_1_3_6_17_1","unstructured":"ISPOR. Modeling Good Research Practices \u2013 Overview. Overview: Report 1; 2017 [17 July 2024]. Available from: https:\/\/www.ispor.org\/heor-resources\/good-practices\/article\/modeling-good-research-practices"},{"key":"e_1_3_6_18_1","unstructured":"Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade. Diretriz de Avalia\u00e7\u00e3o Econ\u00f4mica \u2013 2a edi\u00e7\u00e3o. Diretrizes Metodol\u00f3gicas: minist\u00e9rio da Sa\u00fade; 2014."},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2021.10.165"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_6_21_1","unstructured":"Kite Pharma. Data from: Data on File. ZUMA-1 individual patient data. 2023."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02410-8"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_3_6_26_1","volume-title":"Classifica\u00e7\u00e3o Brasileira Hierarquizada de Procedimentos M\u00e9dicos","author":"Associa\u00e7\u00e3o M\u00e9dica Brasileira","year":"2023","unstructured":"Associa\u00e7\u00e3o M\u00e9dica Brasileira. Classifica\u00e7\u00e3o Brasileira Hierarquizada de Procedimentos M\u00e9dicos. S\u00e3o Paulo (SP): Associa\u00e7\u00e3o M\u00e9dica Brasileira; 2023."},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1909478"},{"key":"e_1_3_6_28_1","unstructured":"Trading Economics. Brazil Consumer Price Index (CPI). 2023. Available from: https:\/\/tradingeconomics.com\/brazil\/consumer-price-index-cpi"},{"key":"e_1_3_6_29_1","unstructured":"Amdahl J. flexsurvcure: flexible parametric cure models. R package version 1.3.1; 2022."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1529674"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1901721"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.015"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_6_34_1","unstructured":"United States Department of Labor. CPI for All Urban Consumers Medical care services. [cited 2023 November 17]. Available from: https:\/\/beta.bls.gov\/dataViewer\/view\/timeseries\/CUSR0000SAM2"},{"key":"e_1_3_6_35_1","unstructured":"OECD. Purchasing power parities (PPP). (Indicator): @OECD; 2024 [cited 2024 April 03]. Available from: http:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.010"},{"key":"e_1_3_6_37_1","unstructured":"Sal\u00e1rio. Enfermeiro - Sal\u00e1rio Brasil; 2024 [cited 2024 December 9]. Available from: https:\/\/www.salario.com.br\/profissao\/enfermeiro-cbo-223505\/#google_vignette"},{"key":"e_1_3_6_38_1","unstructured":"Sal\u00e1rio. M\u00e9dico Cl\u00ednico - Sal\u00e1rio Brasil; 2024. Available from: https:\/\/www.salario.com.br\/profissao\/medico-clinico-cbo-225125\/"},{"key":"e_1_3_6_39_1","volume-title":"Tabela Sintetica - Unidades de ambulatorio","author":"Planserv","year":"2015","unstructured":"Planserv. Tabela Sintetica - Unidades de ambulatorio. Salvador, Bahia, Brazil: governo do Estado da Bahia; 2015."},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002950"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.008"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.702"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01169-z"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.1720"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2290832"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132301"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2260689"},{"key":"e_1_3_6_48_1","unstructured":"Lim F Diong T Ball G et al. Cost-effectiveness and budget-impact analyses of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in Singapore [Poster P1217]. In: European Hematology Association 2024 Congress; 2024 Jun 14\u201317; Madrid Spain. [cited 2025 September 9]. Available from: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/419304\/."},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2305558"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199622"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.45956"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181177"},{"key":"e_1_3_6_53_1","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e.V. Diffuses gro\u00dfzelliges BZell Lymphom Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen. 2024. p. 12\u201315."},{"key":"e_1_3_6_54_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Opinion - TEPKINLY (epcoritamab) for Diffuse large B-cell lymphoma (DLBCL). 2024 [September 23 2024]. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3501630\/en\/tepkinly-epcoritamab-diffuse-large-b-cell-lymphoma-dlbcl"},{"issue":"6","key":"e_1_3_6_55_1","first-page":"1","article-title":"CADTH reimbursement recommendation - Epcoritamab (Epkinly)","volume":"4","author":"Canada\u2019s Drug Agency","year":"2024","unstructured":"Canada\u2019s Drug Agency. CADTH reimbursement recommendation - Epcoritamab (Epkinly). Canadian Journal of Health Technologies. 2024;4(6):1\u201330.","journal-title":"Canadian Journal of Health Technologies"},{"key":"e_1_3_6_56_1","doi-asserted-by":"crossref","unstructured":"da Silva CC Jo\u00e3o Simione A Moreira da Silva Sabaini P et al. Emerging activity of cellular immunotherapy for treatment of cancer in Brazil: Report from the Brazilian Registry. J Bone Marrow Transplant Cell. 2024;5(2):235.","DOI":"10.46765\/2675-374X.2024v5n2p235"},{"key":"e_1_3_6_57_1","volume-title":"Hematol Transfus Cell Ther","author":"Associa\u00e7\u00e3o Brasileira de Hematologia HeTC","year":"2021","unstructured":"Associa\u00e7\u00e3o Brasileira de Hematologia HeTC. A Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular busca a implementa\u00e7\u00e3o e o acesso ao tratamento com CAR\u2011T no Brasil. Hematol Transfus Cell Ther; 2021;43(Suppl 2)."},{"key":"e_1_3_6_58_1","unstructured":"NICE. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. Technology Appraisal Guidance; 2024."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2554516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:45:13Z","timestamp":1766400313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2554516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2554516"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2554516","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}